{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:27:27Z","timestamp":1777922847175,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The Xpert MTB\/RIF test (Cepheid, Sunnyvale, CA) can simultaneously detect the\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) complex DNA and rifampicin (RFP) resistance and can rapidly determine RFP resistance and predict multidrug-resistant tuberculosis (MDR-TB). In this study, we analyzed clinical examination results of a hospital specializing in TB treatment in Wuhan, Hubei, China, and examined the use of traditional culture and drug-sensitive test (DST) results as a gold standard to assess the diagnosis value of the Xpert MTB\/RIF test in RFP resistance and MDR-TB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A total of 2,910 specimens were received in the Mycobacteriology Laboratory, Wuhan Pulmonary Hospital, for Xpert MTB\/RIF testing between December 2013 and December 2014. After the results were reviewed by exclusion criteria, 1,066 Xpert test results were eligible for our study. We then compared the Xpert test results with sputum acid-fast bacilli staining, cultures, and DST results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, Xpert correctly identified 96.71% (147\/152) RFP-resistant TB and 98.25% (898\/914) RFP-sensitive TB specimens. Of the 147 RFP-resistant TB specimens detected by Xpert, 122 MDR-TB (82.99%) were identified by traditional culture and DST techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Xpert can simultaneously detect MTB and RFP resistance with high sensitivity and specificity. Thus, Xpert testing aids in saving a considerable amount of time in the diagnosis and treatment of MDR-TB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2017.0114","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T09:46:05Z","timestamp":1508492765000},"page":"675-679","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB\/RIF in Wuhan, China: A Retrospective Study"],"prefix":"10.1177","volume":"24","author":[{"given":"Hai","family":"Huang","sequence":"first","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyun","family":"Pan","sequence":"additional","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gan","sequence":"additional","affiliation":[{"name":"Wuhan Pulmonary Hospital","place":["China"]},{"name":"Wuhan University","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62639-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40249-016-0103-3","article-title":"Drug-resistant tuberculosis control in China: progress and challenges","volume":"5","author":"Qian L.","year":"2016","unstructured":"Qian L., , Yan Q., , and Lucas H.. 2016. Drug-resistant tuberculosis control in China: progress and challenges. Infect. Dis. Poverty., 5:9.","journal-title":"Infect. Dis. Poverty."},{"key":"e_1_3_3_4_2","unstructured":"World Health Organization. 2016. Global tuberculosis report 2016. Available at www.who.int\/tb\/publications\/global_report\/en."},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"e0148041","DOI":"10.1371\/journal.pone.0148041","article-title":"The prevalence of drug-resistant tuberculosis in mainland china: an updated systematic review and meta-analysis","volume":"11","author":"Duan Q.","year":"2016","unstructured":"Duan Q., , Chen Z., , Chen C., , Zhang Z., , Lu Z., , Yang Y., , and Zhang L.. 2016. The prevalence of drug-resistant tuberculosis in mainland china: an updated systematic review and meta-analysis. PLoS One., 11:e0148041.","journal-title":"PLoS One."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMp1010023","article-title":"Picking up the pace\u2014scale-up of MDR tuberculosis treatment programs","volume":"363","author":"Keshavjee S.","year":"2010","unstructured":"Keshavjee S., , and Farmer P.E.. 2010. Picking up the pace\u2014scale-up of MDR tuberculosis treatment programs. N. Engl. J. Med., 363:1781\u20131784.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_7_2","unstructured":"World Health Organization. 2011. Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB\/RIF System. World Health Organization Geneva Switzerland."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60438-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JCM.43.8.3699-3703.2005","article-title":"Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates","volume":"43","author":"Hillemann D.","year":"2005","unstructured":"Hillemann D., , Weizenegger M., , Kubica T., , Richter E., , and Niemann S.. 2005. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol., 43:3699\u20133703.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(13)70119-X","article-title":"Assessment of the sensitivity and specificity of Xpert MTB\/RIF assay as an early sputum biomarker of response to tuberculosis treatment","volume":"1","author":"Friedrich S.O.","year":"2013","unstructured":"Friedrich S.O., , Rachow A., , Saathoff E., , Singh K., , Mangu C.D., , Dawson R., , Phillips P.P.J., , Venter A., , Bateson A., , Boehme C.C., , Heinrich N., , Hunt R.D., , Boeree M.J., , Zumla A., , McHugh T.D., , Gillespie S.H., , Diacon A.H., , and Hoelscher M.. 2013. Assessment of the sensitivity and specificity of Xpert MTB\/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir. Med., 1:462\u2013470.","journal-title":"Lancet Respir. Med."},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5588\/ijtld.13.0853","article-title":"False-positive Xpert\u00ae MTB\/RIF assays in previously treated patients: need for caution in interpreting results","volume":"18","author":"Boyles T.H.","year":"2014","unstructured":"Boyles T.H., , Hughes J., , Cox V., , Burton R., , Meintjes G., , and Mendelson M.. 2014. False-positive Xpert\u00ae MTB\/RIF assays in previously treated patients: need for caution in interpreting results. Int. J. Tuberc. Lung Dis., 18:876\u2013878.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01463-09"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907847"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.4.496"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1099\/00222615-47-3-189","article-title":"The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis\u2014a molecular story","volume":"47","author":"Drobniewski F.A.","year":"1998","unstructured":"Drobniewski F.A., , and Wilson S.M.. 1998. The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis\u2014a molecular story. J. Med. Microbiol., 47:189\u2013196.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.3760\/cma.j.issn.0366-6999.20141004","article-title":"Evaluation of the Xpert MTB\/RIF assay for diagnosis of tuberculosis and rifampin resistance in county-level laboratories in Hunan province, China","volume":"127","author":"Hu P.","year":"2014","unstructured":"Hu P., , Bai L., , Liu F., , Ou X., , Zhang Z., , Yi S., , Chen Z., , Gong D., , Liu B., , Guo J., , and Tan Y.. 2014. Evaluation of the Xpert MTB\/RIF assay for diagnosis of tuberculosis and rifampin resistance in county-level laboratories in Hunan province, China. Chin. Med. J., 127:3744\u20133750.","journal-title":"Chin. Med. J."},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3201\/eid2203.151227","article-title":"Decreased time to treatment initiation for multidrug-resistant tuberculosis patients after use of Xpert MTB\/RIF test, Latvia","volume":"22","author":"Stagg H.R.","year":"2016","unstructured":"Stagg H.R., , White P.J., , Rieksti\u0146a V., , C\u012brule A., , \u0160\u0137enders \u0122., , Leimane V., , Kuksa L., , Dravniece G., , Brown J., , and Jackson C.. 2016. Decreased time to treatment initiation for multidrug-resistant tuberculosis patients after use of Xpert MTB\/RIF test, Latvia. Emerg. Infect. Dis., 22:482\u2013490.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_3_18_2","unstructured":"World Health Organization. 2011. Rapid Implementation of the Xpert MTB\/RIF diagnostic test: technical and Operational \u201cHow-to\u201d Practical considerations. Available at http:\/\/who.int\/tb\/publications\/tb-amplificationtechnology-implementation\/en."},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2016.01.009","article-title":"False-positive rifampin resistant results with Xpert MTB\/RIF version 4 assay in clinical samples with a low bacterial load","volume":"85","author":"Ocheretina O.","year":"2016","unstructured":"Ocheretina O., , Byrt E., , Mabou M.M., , Royalmardi G., , Merveille Y.M., , Rouzier V., , Fitzgerald D., , and Pape J.W.. 2016. False-positive rifampin resistant results with Xpert MTB\/RIF version 4 assay in clinical samples with a low bacterial load. Diagn. Microbiol. Infect. Dis., 85:53\u201355.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"e28815","DOI":"10.1371\/journal.pone.0028815","article-title":"Comparison of quantitative techniques including Xpert MTB\/RIF to evaluate mycobacterial burden","volume":"6","author":"van Zyl-Smit R.N.","year":"2011","unstructured":"van Zyl-Smit R.N., , Binder A., , Meldau R., , Mishra H., , Semple P.L., , Theron G., , Peter J., , Whitelaw A., , Sharma S.K., , Warren R., , and Bateman E.D.. 2011. Comparison of quantitative techniques including Xpert MTB\/RIF to evaluate mycobacterial burden. PLoS One., 6:e28815.","journal-title":"PLoS One."},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"e0144656","DOI":"10.1371\/journal.pone.0144656","article-title":"Implementing the Xpert\u00ae MTB\/RIF diagnostic test for tuberculosis and rifampicin resistance: outcomes and lessons learned in 18 countries","volume":"10","author":"Ardizzoni E.","year":"2015","unstructured":"Ardizzoni E., , Emmanuel F., , Peter S., , Martina C., , Anne-Laure P., , Francis V., , Cara S.K., , and Pamela H.. 2015. Implementing the Xpert\u00ae MTB\/RIF diagnostic test for tuberculosis and rifampicin resistance: outcomes and lessons learned in 18 countries. PLoS One., 10:e0144656.","journal-title":"PLoS One."},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"e109736","DOI":"10.1371\/journal.pone.0109736","article-title":"Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study","volume":"9","author":"Wu J.","year":"2014","unstructured":"Wu J., , Zhang Y., , Li J., , Lin S., , Wang L., , Jiang Y., , Pan Q., , and Shen X.. 2014. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study. PLoS One., 9:e109736.","journal-title":"PLoS One."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2017.0114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:31:53Z","timestamp":1777667513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2017.0114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1089\/mdr.2017.0114"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2017.0114","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}